Are Pharma Companies Too Big to Innovate?

Does size matter when it comes to innovation in the pharmaceutical industry?

Jan 2, 2014 at 2:33PM

Ask any investor what they think about Johnson & Johnson (NYSE:JNJ), and you'll probably hear that it's a diversified pharma company, a blue-chip stock that pays a hefty dividend, and it's a relatively safe investment for investors looking for exposure to the health-care sector. But you might also hear investors criticize its size. With a market cap of almost $260 billion, Johnson & Johnson is one of the largest companies in the U.S., and it edges out both Merck and Pfizer as the largest pharma company in the Dow. Can a company this massive be nimble and entrepreneurial enough to innovate? Is its size holding back its long-term potential to bring new products to market?

Looking at Johnson & Johnson's stellar performance in 2013 and its growing pharmaceutical division, size doesn't seem to be a problem here. In fact, Bernard Munos, innovation expert and founder of the InnoThink Center for Research in Biomedical Innovation, doesn't believe that it's impossible for a large company to innovate. He thinks investors are better served looking at a company's culture and leadership, citing historical examples from Merck and Roche's subsidiary Genentech. In the following interview, Munos further explains why size doesn't matter when it comes to innovation. A transcript follows the video.

The Motley Fool's top stock pick for 2014
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

Max Macaluso: Bernard, we've been talking a lot about innovation, companies that have embraced it in the Big Pharma industry. I'm curious, is it possible to be too big to innovate? Do you look at a company like Johnson & Johnson, for instance; its market cap is enormous. You look at Merck. Merck is so diversified -- they do pharmaceuticals, consumer health, also animal health -- is it difficult to innovate when you're that big? Is it impossible to innovate when you're that large?

Bernard Munos: It's not. But you've got to keep in mind that, when it comes to innovation, the critical mass is one human brain. It's not 1,000 people. It's one human brain. This is why Rockefeller does it so well. They've got 75 outstanding brains that spin out one Nobel Prize after the other.

I think the pharmaceutical industry over the last 15 years, certainly the large companies, have tended to forget that. In fact, they have purged their "mad scientists," so to speak, because those people tend to be tough to manage, because they always have a different idea.

The leaders of the industry fail to recognize that this is the critical ingredient that you need in order to spur innovation, so they got rid of them and they ended up with lots of people that were easier to manage, but didn't produce anything; hence, this industrywide innovation crisis.

Look at Merck when Vagelos was managing it. It was a big company, one of the biggest ones in the industry, and yet it performed extremely well. At $100 billion market cap, Genentech was not small, and yet it kept coming with one breakthrough after the other.

It's all about leadership. I think wherever you have effective leadership, size doesn't matter. You can have an innovative culture and organization that will produce breakthroughs. If the leadership isn't there, you're not going to get that. It doesn't matter how much money you throw at it, it doesn't matter the processes that you've got. It doesn't matter how many times you reorganize the organization. It just isn't going to work.

Max Macaluso, Ph.D. and Bernard Munos have no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers